NCT04596007已完成1 期
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC83518 Tablets in Chinses Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- The Number of Adverse Events (AEs)
研究概览
简要总结
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
All are double-blind except the pre-trial group
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who are willing and are able to provide a written informed consent to participate in the study.
- •Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial.
- •Subjects aged between 18 and 45 (both inclusive) years old.
- •Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥18 and ≤28 kg/m2 at screening.
- •Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).
排除标准
- •Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP antibodies at screening.
- •Subjects with history of digestive system,urinary system, liver,central nervous system, blood system, endocrine system,respiratory system,immune system,cardiovascular system,and/or malignant tumor or others medical conditions (such as history of mental illness, etc.) that are not suitable for clinical trial participation;Subjects with history of stroke, epilepsy, bipolar disorder/mania, high intraocular pressure, or acute angular-closure glaucoma.
- •Subjects with history of sleep-related illness.
- •Subjects with history of severe involuntary hypoglycemia
- •Known allergic reactions or hypersensitivity to any excipient of the drug formulation(s) ,or anaphylaxis physique.
- •Use of any prescription or non-prescription medications within 14 days prior to initial dosing,or Use of any medications known to inhibit or induce cytochrome P enzyme drug metabolism within 28 days prior to initial dosing.
- •Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
- •Positive results from urine drug screen test.
- •History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of > 21 units/week), or positive results from alcohol breath test.
- •Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug.
- •Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
- •Subjects who plan to receive or have had organ transplants.
- •Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential.
- •Subjects who participated in another clinical trial within 3 months prior to initial dosing.
- •Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.
研究组 & 干预措施
HEC83518 tablets
Experimental
There will be a total of 7 dose cohorts: 5 mg,10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
干预措施: HEC83518 tablets (Drug)
placebo tablets
Placebo Comparator
There will be a total of 6 dose cohorts: 10 mg, 20 mg, 40 mg, 80 mg, and 140 mg,200 mg.
干预措施: Placebo (Drug)
结局指标
主要结局
The Number of Adverse Events (AEs)
时间窗: up to 5 days
Safety and Tolerability of HEC83518 by Assessment of the Number of Adverse Events (AEs) Following Administration in Single Ascending Dose .
次要结局
- PK parameters -tmax(up to 96 hours)
- PK parameters -Vz/F(up to 96 hours)
- PK parameters - MRT(up to 96 hours)
- PK parameters -CL/F(up to 96 hours)
- PK parameters -t½(up to 96 hours)
- PK parameters - AUC0-∞(up to 96 hours)
- PK parameters - Cmax(up to 96 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 TabletsInsomniaNCT04667429Sunshine Lake Pharma Co., Ltd.57
已完成
1 期
The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy SubjectsMajor Depressive DisorderNCT04591301Sunshine Lake Pharma Co., Ltd.69
已完成
1 期
HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy VolunteersHealthyNCT03886688Sunshine Lake Pharma Co., Ltd.116
已完成
1 期
Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.HemodialysisPeritoneal DialysisNCT04925674Sunshine Lake Pharma Co., Ltd.60
已完成
1 期
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult SubjectsNonalcoholic Steatohepatitis (NASH)NCT04546984Sunshine Lake Pharma Co., Ltd.66